To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Extreme Hypofractionation… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer: Early Toxicity Results from the Scandinavian Randomized Phase III Trial “HYPO-RT-PC”

Conference paper
Authors A. Widmark
A. Gunnlaugsson
L. Beckman
C. Thellenberg-Karlsson
M. Hoyer
M. Lagerlund
P. Fransson
Jon Kindblom
C. Ginman
B. Johansson
M. Seke
K. Björnlinger
E. Kjellén
L. Franzen
P. Nilsson
Published in International Journal of Radiation Oncology, Biology, Physics, 96 (5), s. 938–939
ISSN 0360-3016
Publication year 2016
Published at Institute of Clinical Sciences, Department of Oncology
Language en
Subject categories Cancer and Oncology, Radiology, Nuclear Medicine and Medical Imaging


Prostate cancer is postulated to have high radiation-fractionation sensitivity, which suggests a potential therapeutic benefit for hypofractionated (HF) radiotherapy (RT). Results from randomized studies investigating efficacy and side effects of moderately hypofractionated (M-HF) schedules have recently been reported in the literature. Data from randomized trials with extreme hypofractionation (E-HF) are however hitherto lacking. We here report two-year toxicity results from the Scandinavian multicenter phase III trial (HYPO-RT-PC) comparing E-HF with conventional fractionation (CF).

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?